Treatment - Page 34 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

Posted by on Oct 17, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...

Read More

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Posted by on Oct 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The review aimed to assess chemotherapy-free treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL).   Some background Standard therapy for slow-growing non-Hodgkin lymphoma (NHL) such as FL and MZL involves immunochemotherapy (ICT). ICT combines immunotherapy and chemotherapy treatments. However, many patients...

Read More

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Posted by on Oct 17, 2021 in Breast cancer | 0 comments

In a nutshell The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients.  Some background Breast cancer (BC) is the most common tumor in women...

Read More

Reviewing focal therapies for patients with localized prostate cancer.

Reviewing focal therapies for patients with localized prostate cancer.

Posted by on Oct 16, 2021 in Prostate cancer | 0 comments

In a nutshell This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness.  Some background FT includes alternative, non-invasive methods for treating PCa. High-intensity focused ultrasound (HIFU) is a radiation-free technique that uses high-frequency ultrasound...

Read More

How beneficial are foot-ankle flexibility and resistance exercises for preventing foot diabetic ulcer recurrence?

How beneficial are foot-ankle flexibility and resistance exercises for preventing foot diabetic ulcer recurrence?

Posted by on Oct 16, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effect of foot-ankle flexibility and resistance exercises in the prevention and recurrence of plantar foot-diabetic ulcers. The authors concluded that foot-ankle flexibility and resistance exercises can reduce the recurrence of plantar foot-diabetic ulcers and improve diabetic neuropathy (DN; nerve damage) and...

Read More

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...

Read More

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus fluorouracil and folinic acid in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus fluorouracil and folinic acid in patients with RAS wild-type metastatic colorectal cancer.

Posted by on Oct 16, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of panitumumab (Vectibix) when added to maintenance therapy with fluorouracil (Adrucil) and folinic acid (Leucovirin) (FU/FA) in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with FU/FA plus panitumumab was safe and...

Read More

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...

Read More

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Posted by on Oct 16, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor